SI2961752T1 - Substituirani imidazopiridazini - Google Patents

Substituirani imidazopiridazini Download PDF

Info

Publication number
SI2961752T1
SI2961752T1 SI201430509T SI201430509T SI2961752T1 SI 2961752 T1 SI2961752 T1 SI 2961752T1 SI 201430509 T SI201430509 T SI 201430509T SI 201430509 T SI201430509 T SI 201430509T SI 2961752 T1 SI2961752 T1 SI 2961752T1
Authority
SI
Slovenia
Prior art keywords
tumors
compound
formula
disease
general formula
Prior art date
Application number
SI201430509T
Other languages
English (en)
Inventor
Marcus Koppitz
Ulrich Klar
Antje Margret Wengner
Roland Neuhaus
Gerhard Siemeister
Michael Bruning
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50179606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2961752(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of SI2961752T1 publication Critical patent/SI2961752T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

  1. ·"···· ··· Bayer Pharma Aktiengeselschaft EP 2 961 752 BI Mulerstrasse 178 MIP - 9451 - SI 13353 Berlin, DE Substituirani imidazopiridazini Patentni zahtevki
    1. Spojina s splošno formulo (Β):
    (B) ali njen N-oksid, hidrat, solvat ali njena sol.
  2. 2. Spojina po zahtevku 1, ali njena farmacevtsko sprejemljiva sol, za uporabo v zdravljenju ali profilaksi bolezni.
  3. 3. Spojina za uporabo po zahtevku 2, ali njena farmacevtsko sprejemljiva sol, kjer je omenjena bolezen: bolezen bolezen nekontrolirane rasti celic, proliferacija in/ali preživetje, neprimeren celični imunski odgovor, ali neprimeren celični vnetni odgovor, še posebej kjer je nekontrolirana rast celic, proliferacija in/ali preživetje, neprimeren celični imunski odgovor, ali neprimeren celični vnetni odgovor posredovan s strani z mitogenom-aktivirane poti protein kinaze (MEK-ERK), še bolj natančno, kjer je nekontrolirana rast celic, proliferacija in/ali preživetje, neprimeren celični imunski odgovor, ali neprimeren celični vnetni ······ ··· odgovor hematološki tumor, trden tumor in/ali njune metastaze, kot na primer levkemije in mielodisplastični sindrom, maligni limfomi, tumorji glave in vratu, vključno z možganskimi tumorji in možganske metastaze, tumorje toraksa, vključno z nedrobnoceličnimi in drobnoceličnimi pljučnim tumorji, gastrointestinal tumorji, endokrinimi tumorji, tumorji mlečne žleze in drugi ginekoliški tumorji, urološki tumourji, vključno z ledvičnimi tumorji, tumorji mehurja in prostate, kožni tumorji in sarkomi in/ali njihove metastaze.
  4. 4. Farmacevtski sestavek, ki vsebuje spojino po zahtevku 1, ali njeno farmacevtsko sprejemljivo sol in farmacevtsko sprejemljivo redčilo ali nosilec.
  5. 5. Farmacevtska kombinacij a, ki vsebuj e: spojina po zahtevku 1 ali njeno farmacevtsko sprejemljivo sol; in eno ali več sredstev izbrano iz skupine, ki vsebuje: taksan, kot na primer docetaksel, paklitaksel ali taksol; epotilon, kot na primer iksabepilon, patupilon ali sagopilon; mitoksantron; predinizolon; deksametazon; estramustin; vinblastin; vinkristin; doksorubicin; adriamicin; idarubicin; daunorubicin; bleomicin; etoposid; ciklofosfamid; ifosfamid; prokarbazin; melfalan; 5-fluorouracil; kapecitabin; fludarabin; citarabin; 2-kloro-2'-deoksiadenozin; tiogvanin; anti-androgen, kot na primer flutamid, ciproteron acetate ali bikalutamid; bortezomib; derivat platine, kot na primer cisplatin ali karboplatin; klorambucil; metotreksat in rituksimab.
  6. 6. Postopek priprave spojine po zahtevku 1, kjer omenjeni postopek obsega korak omogočanja vmesni spojini s formulo (Β1):
    ............. v kateri Z' predstavlja skupino izbrani izmed: -C(=0)0H in -C(=0)0-(Ci-C6-alkil); da reagira s spojino s formulo Ib:
    Ib da tako, po neobvezni deprotekciji, dobimo spojino s formulo (B), kot je opisana v zahtevku 1.
  7. 7. Postopek priprave spojine po zahtevku 1, kjer omenjeni postopek obsega korak omogočanja vmesni spojini s splošno formulo (Β2):
    (B2) v kateri je Q2 predstavlja halogen atom; reagirati s spojino s splošno formulo Ha :
    v kateri je Y substituent, ki je v reakciji premaknjen, izbran iz skupine, ki vsebuje skupino boronske kisline, ali skupino estra boronske kisline; da tako, po neobvezni deprotekciji, dobimo spojino s formulo (B), kot je opisana v zahtevku 1.
  8. 8. Postopek priprave spojine po zahtevku 1, kjer omenjeni postopek obsega korak pretvorbe vmesne spojine s splošno formulo (Β3): ' ' «·· > a 4 . .
    ·*·· ··· (Β3) v kateri Q* predstavlja halogen atom; da reagira s spojino s splošno formulo (Β4):
    (B4) da tako, po neobvezni deprotekciji, dobimo spojino s formulo (B), kot je opisana v zahtevku 1.
  9. 9. Postopek priprave spojine po zahtevku 1, kjer omenjeni postopek obsega korak pretvorbe vmesne spojine s splošno formulo (Β5):
    (B5) v kateri Q3 predstavlja skupino a NH2; da reagira s spojino s splošno formulo (Β6):
    ··· ···· ··· , (Β6) da tako, po redukciji imina in po neobvezni deprotekciji, dobimo spojino s formulo (B), kot je opisana v zahtevku 1.
  10. 10. Postopek priprave spojine po zahtevku 1, kjer omenjeni postopek obsega korak pretvorbe vmesne spojine s splošno formulo (Β7):
    (B7) v kateri R3 predstavlja jodov, bromov ali klorov atom; da reagira s spojino s formulo (Β8):
    (B8) v kateri je Y substituent, ki je v reakciji spajanja premaknjen, izbran iz skupine, ki vsebuje atom vodika, ali skupino boronske kisline, ali skupino boronskega estra; da dobimo spojino s formulo (B), kot je opisana v zahtevku 1.
  11. 11. Uporaba spojine po zahtevku 1, ali njene farmacevtsko sprejemljive soli, za pripravo zdravila za profilakso ali zdravljenje bolezni. * * * ·βα «... ···· ···
  12. 12. Uporaba po zahtevku 11, kjer je omenjena bolezen: bolezen nenadzorovane rasti celic, proliferacija in/ali preživetje, neprimeren celični imunski odgovor ali neprimeren celični vnetni odgovor, še posebej kjer je bolezen nenadzorovane rasti celic, proliferacija in/ali preživetje, neprimeren celični imunski odgovor ali neprimeren celični vnetni odgovor, posredovan s strani z mitogenom-aktivirane poti protein kinaze (MEK-ERK), bolj natančno kjer je bolezen nenadzorovane rasti celic, proliferacija in/ali preživetje, neprimeren celični imunski odgovor ali neprimeren celični vnetni odgovor, hematološki tumor, čvrst tumor in/ali njegove metastaze, kot na primer levkemije in mielodisplastični sindrom, maligni limfomi, tumoiji glave in vratu, vključno z možganskimi tumoiji in možganskimi metastazami, tumorji toraksa, vključno z nedrobnoceličnimi in drobnoceličnimi pljučnimi tumorji, gastrointestinalnimi tumoiji, endokrinimi tumorji, tumoiji dojk in drugi ginekološki tumorji, urološki tumoiji vključno z ledvičnimi, tumorji mehuija in prostate, kožni tumoiji in sarkomi in/ali njihove metastaze.
  13. 13. Spojina s formulo (BI), (B2), (B3) ali (B5), kot je opisana v zahtevkih 6, 7, 8 in 9.
SI201430509T 2013-03-01 2014-02-25 Substituirani imidazopiridazini SI2961752T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13157453 2013-03-01
EP13198930 2013-12-20
EP14706569.2A EP2961752B1 (en) 2013-03-01 2014-02-25 Substituted imidazopyridazines
PCT/EP2014/053573 WO2014131739A2 (en) 2013-03-01 2014-02-25 Substituted imidazopyridazines

Publications (1)

Publication Number Publication Date
SI2961752T1 true SI2961752T1 (sl) 2018-01-31

Family

ID=50179606

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201430509T SI2961752T1 (sl) 2013-03-01 2014-02-25 Substituirani imidazopiridazini

Country Status (36)

Country Link
US (1) US9512130B2 (sl)
EP (1) EP2961752B1 (sl)
JP (1) JP2016511252A (sl)
KR (1) KR20150125654A (sl)
CN (1) CN105008364B (sl)
AP (1) AP2015008636A0 (sl)
AU (1) AU2014222806A1 (sl)
BR (1) BR112015020990A2 (sl)
CA (1) CA2902978A1 (sl)
CL (1) CL2015002433A1 (sl)
CR (1) CR20150455A (sl)
CU (1) CU20150094A7 (sl)
CY (1) CY1119667T1 (sl)
DK (1) DK2961752T3 (sl)
EA (1) EA029027B1 (sl)
ES (1) ES2651765T3 (sl)
GT (1) GT201500247A (sl)
HK (1) HK1213876A1 (sl)
HR (1) HRP20171890T1 (sl)
HU (1) HUE037417T2 (sl)
IL (1) IL240348A0 (sl)
LT (1) LT2961752T (sl)
MX (1) MX2015011316A (sl)
NI (1) NI201500118A (sl)
NO (1) NO2961752T3 (sl)
PE (1) PE20151759A1 (sl)
PH (1) PH12015501913A1 (sl)
PL (1) PL2961752T3 (sl)
PT (1) PT2961752T (sl)
RS (1) RS56665B1 (sl)
SG (1) SG11201505882QA (sl)
SI (1) SI2961752T1 (sl)
TN (1) TN2015000371A1 (sl)
TW (1) TW201437211A (sl)
UY (1) UY35360A (sl)
WO (1) WO2014131739A2 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510034QA (en) * 2013-06-13 2016-01-28 Bayer Pharma AG Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer
TW201613927A (en) 2014-09-01 2016-04-16 Bayer Pharma AG Method for preparation of substituted imidazopyridazines
US10485880B2 (en) 2014-12-15 2019-11-26 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
CN107921145A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物（adc）
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
EP3919518A1 (en) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN110072556B (zh) 2016-12-21 2023-05-02 拜耳制药股份公司 具有ksp抑制剂的特异性抗体药物缀合物(adc)
BR112019012883A2 (pt) 2016-12-21 2019-11-26 Bayer Ag conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis
AR112217A1 (es) * 2017-06-30 2019-10-02 Servier Lab Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3104759A1 (de) * 1981-02-11 1982-08-19 Bayer Ag, 5090 Leverkusen Dihalogenierte imidazolcarbonsaeure-amide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
JP2830210B2 (ja) * 1989-11-17 1998-12-02 日本曹達株式会社 α，β―不飽和ケトン類の合成法
US6068834A (en) * 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
FR2804955B1 (fr) * 2000-02-11 2003-02-14 Rhodia Chimie Sa Procede de fonctionnalisation d'une double liaison
CN101541801A (zh) * 2006-08-04 2009-09-23 武田药品工业株式会社 稠杂环衍生物及其用途
US8389527B2 (en) * 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
EP2547685A1 (en) * 2010-03-15 2013-01-23 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
JP5583845B2 (ja) * 2010-04-28 2014-09-03 ブリストル−マイヤーズ スクイブ カンパニー イミダゾピリダジニル化合物および癌に対するそれらの使用
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9156837B2 (en) * 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2014020041A1 (en) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer

Also Published As

Publication number Publication date
PE20151759A1 (es) 2015-12-20
GT201500247A (es) 2017-10-05
EP2961752B1 (en) 2017-09-13
TW201437211A (zh) 2014-10-01
BR112015020990A2 (pt) 2017-07-18
PT2961752T (pt) 2017-12-18
EP2961752A2 (en) 2016-01-06
DK2961752T3 (en) 2017-12-11
AU2014222806A1 (en) 2015-09-03
CL2015002433A1 (es) 2016-01-04
JP2016511252A (ja) 2016-04-14
SG11201505882QA (en) 2015-09-29
WO2014131739A3 (en) 2014-12-04
CA2902978A1 (en) 2014-09-04
NO2961752T3 (sl) 2018-02-10
CN105008364B (zh) 2017-11-07
PL2961752T3 (pl) 2018-02-28
PH12015501913A1 (en) 2016-01-04
CN105008364A (zh) 2015-10-28
EA029027B1 (ru) 2018-01-31
HUE037417T2 (hu) 2018-08-28
EA201591618A1 (ru) 2016-02-29
AP2015008636A0 (en) 2015-08-31
KR20150125654A (ko) 2015-11-09
IL240348A0 (en) 2015-09-24
ES2651765T3 (es) 2018-01-29
MX2015011316A (es) 2015-12-03
CU20150094A7 (es) 2016-05-30
CR20150455A (es) 2015-10-26
UY35360A (es) 2014-09-30
HK1213876A1 (zh) 2016-07-15
LT2961752T (lt) 2017-12-27
HRP20171890T1 (hr) 2018-01-12
CY1119667T1 (el) 2018-04-04
RS56665B1 (sr) 2018-03-30
US20160016959A1 (en) 2016-01-21
US9512130B2 (en) 2016-12-06
WO2014131739A2 (en) 2014-09-04
TN2015000371A1 (en) 2017-01-03
NI201500118A (es) 2015-10-19

Similar Documents

Publication Publication Date Title
SI2961752T1 (sl) Substituirani imidazopiridazini
HRP20210848T1 (hr) Sastavi i postupci za sprječavanje aktivnosti arginaze
JP2014513704A5 (sl)
JP2016514719A5 (sl)
JP2012153722A5 (sl)
JP2016538344A5 (sl)
CN102333759A (zh) 用于抑制nhe介导的反向转运以治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
CN107427003B (zh) 联合治疗
JP2015512943A5 (sl)
JP2014510774A5 (sl)
UA120423C2 (uk) Комбінація інгібітора mek та інгібітора erk для застосування в лікуванні гіперпроліферативних захворювань
JP2016521275A5 (sl)
Bhattacharyya et al. Effect of glucosamine conjugation to zinc (II) complexes of a bis-pyrazole ligand: Syntheses, characterization and anticancer activity
JP2016190843A5 (sl)
WO2017093443A1 (en) Melflufen dosage regimens for cancer
Morais et al. Important cytotoxic and cytostatic effects of new copper (i)–phosphane compounds with N, N, N, O and N, S bidentate ligands
SI3174881T1 (sl) (1,2,4)triazolo(4,3-B)piridazini za uporabo v zdravljenu proliferativnih bolezni
JP2013545775A5 (sl)
WO2012028874A1 (en) Cytotoxic luminescent metal complexes
KR20170118700A (ko) (1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도
JP2016172741A5 (sl)
JP7085242B2 (ja) キナーゼ活性を阻害するためのアリールホスフィンオキシド
Bronisz 1, 4-Di (1, 2, 3, 4-tetrazol-2-yl) butane as a precursor of new 2D and 3D coordination polymers of Cu (II)
CN105481902B (zh) 以磷酸二氢根为轴向配体的铂(iv)抗癌化合物
Yadav et al. Anti-leishmanial activity of Ni (ii), Pd (ii) and Pt (ii) β-oxodithioester complexes